143 related articles for article (PubMed ID: 16837557)
1. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557
[TBL] [Abstract][Full Text] [Related]
2. Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
Lai A; Sum J; Fan H; McIntosh JM; Quik M
Neuroscience; 2004; 127(2):399-408. PubMed ID: 15262330
[TBL] [Abstract][Full Text] [Related]
3. Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites.
Kulak JM; McIntosh JM; Quik M
Mol Pharmacol; 2002 Jan; 61(1):230-8. PubMed ID: 11752225
[TBL] [Abstract][Full Text] [Related]
4. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum.
O'Leary K; Parameswaran N; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2008 May; 325(2):646-54. PubMed ID: 18305015
[TBL] [Abstract][Full Text] [Related]
5. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
McCallum SE; Parameswaran N; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2005 Sep; 68(3):737-46. PubMed ID: 15933214
[TBL] [Abstract][Full Text] [Related]
6. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
Bordia T; Grady SR; McIntosh JM; Quik M
Mol Pharmacol; 2007 Jul; 72(1):52-61. PubMed ID: 17409284
[TBL] [Abstract][Full Text] [Related]
7. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Quik M; Chen L; Parameswaran N; Xie X; Langston JW; McCallum SE
J Neurosci; 2006 Apr; 26(17):4681-9. PubMed ID: 16641249
[TBL] [Abstract][Full Text] [Related]
8. Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage.
Quik M; Polonskaya Y; McIntosh JM; Kulak JM
Neuroscience; 2002; 112(3):619-30. PubMed ID: 12074903
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys.
McCallum SE; Parameswaran N; Bordia T; Fan H; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Jul; 318(1):381-8. PubMed ID: 16622038
[TBL] [Abstract][Full Text] [Related]
10. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.
Huang LZ; Parameswaran N; Bordia T; Michael McIntosh J; Quik M
J Neurochem; 2009 May; 109(3):826-37. PubMed ID: 19250334
[TBL] [Abstract][Full Text] [Related]
11. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.
Quik M; Sum JD; Whiteaker P; McCallum SE; Marks MJ; Musachio J; McIntosh JM; Collins AC; Grady SR
Mol Pharmacol; 2003 May; 63(5):1169-79. PubMed ID: 12695545
[TBL] [Abstract][Full Text] [Related]
12. L-DOPA treatment modulates nicotinic receptors in monkey striatum.
Quik M; Bordia T; Okihara M; Fan H; Marks MJ; McIntosh JM; Whiteaker P
Mol Pharmacol; 2003 Sep; 64(3):619-28. PubMed ID: 12920198
[TBL] [Abstract][Full Text] [Related]
13. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA
J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311
[TBL] [Abstract][Full Text] [Related]
14. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
Quik M; Polonskaya Y; Kulak JM; McIntosh JM
J Neurosci; 2001 Aug; 21(15):5494-500. PubMed ID: 11466420
[TBL] [Abstract][Full Text] [Related]
15. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs.
Khwaja M; McCormack A; McIntosh JM; Di Monte DA; Quik M
J Neurochem; 2007 Jan; 100(1):180-90. PubMed ID: 17227438
[TBL] [Abstract][Full Text] [Related]
16. Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA.
Quik M; Vailati S; Bordia T; Kulak JM; Fan H; McIntosh JM; Clementi F; Gotti C
Mol Pharmacol; 2005 Jan; 67(1):32-41. PubMed ID: 15470079
[TBL] [Abstract][Full Text] [Related]
17. α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.
Marks MJ; Grady SR; Salminen O; Paley MA; Wageman CR; McIntosh JM; Whiteaker P
J Neurochem; 2014 Jul; 130(2):185-98. PubMed ID: 24661093
[TBL] [Abstract][Full Text] [Related]
18. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes.
Sharples CG; Kaiser S; Soliakov L; Marks MJ; Collins AC; Washburn M; Wright E; Spencer JA; Gallagher T; Whiteaker P; Wonnacott S
J Neurosci; 2000 Apr; 20(8):2783-91. PubMed ID: 10751429
[TBL] [Abstract][Full Text] [Related]
19. Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage.
Kulak JM; Musachio JL; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2002 Nov; 303(2):633-9. PubMed ID: 12388645
[TBL] [Abstract][Full Text] [Related]
20. Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage.
Quik M; Campos C; Parameswaran N; Langston JW; McIntosh JM; Yeluashvili M
J Mol Neurosci; 2010 Jan; 40(1-2):105-13. PubMed ID: 19685015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
